507 / 1266
Relapsed GBM after RT-TMZ
•
No established standard
–
re-resection +/- carmustine wafers?
–
PCV?
–
various studies of chemo + bevacizumab
•
High response rates but no clear survival benefit
–
cediranib (VEGFR inhibitor) +/- CCNU:
•
no benefit
–
other studies of EGFR TK inhibitors
•
erlotinib associated with
reduced
PFS (van den Bent JCO 2009)
–
TMZ rechallenge +/- altered temozolomide scheduling?
Opportunity to test novel agents